Skip to main content

Advertisement

Table 1 Intention-to-treat and per-protocol analysis of FGF2 and VEGF concentrations between high and moderate volume exercise groups in BETA (n = 386)

From: The impact of exercise on growth factors (VEGF and FGF2): results from a 12-month randomized intervention trial

Group n Baseline 6 Months 12 Months Treatment Effect Between-Group P c
Geo-metric Mean a 95% CI Geo-metric Mean 95% CI Geo-metric Mean 95% CI Ratio of High/Moderate b 95% CI
Intention-to-treat
FGF2
 High 195 121.3 114.4–128.5 116.1 110.1–122.4 123.3 117.7–129.2 0.98 0.94–1.02 0.28
 Moderate 191 118.8 111.9–126.2 122.9 116.2–130.0 120.1 113.1–127.6    
VEGF
 High 195 62.3 55.1–70.4 58.5 51.7–66.3 58.6 51.3–66.9 0.94 0.86–1.02 0.15
 Moderate 191 64.9 57.2–73.6 63.6 55.7–72.6 67.3 58.9–76.9    
Per-protocol d
FGF2 0.64
 High 80 119.8 110.8–129.4 116.0 107.3–125.3 121.2 113.5–129.4 1.02 0.95–1.10
 Moderate 58 112.6 100.0–126.7 113.9 101.9–127.3 109.6 98.3–122.2   
VEGF 0.74
 High 80 60.6 50.8–72.3 60.6 50.0–73.4 58.0 47.6–70.7 0.98 0.84–1.13
 Moderate 58 70.3 54.2–91.0 64.9 49.9–84.6 74.0 56.9–96.3   
  1. a. Geometric mean of FGF2 and VEGF was in the unit of pg/mL
  2. b. The geometric mean ratios were estimated from least square means for the difference in treatment effect between high and moderate volume exercisers averaged across the entire study period adjusted for the baseline values and then back log-transformed
  3. c. P value corresponds to the null hypothesis that the ratio of treatment effect between high- and moderate-volume groups equals 1 against the 2-sided alternative hypothesis
  4. d. Women assigned to the moderate-volume group were adherent if they completed 90 to 100% of the exercise prescription (mean, 135–150 min/wk), weeks 13 to 52 at full prescription; women assigned to the high-volume group were adherent if they completed at least 90% of the exercise prescription (mean, ≥270 min/wk), weeks 13 to 52 at full prescription